Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02541825
Other study ID # BeijingShijitan
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received September 3, 2015
Last updated September 3, 2015
Start date August 2015
Est. completion date December 2017

Study information

Verified date September 2015
Source Beijing Shijitan Hospital
Contact n/a
Is FDA regulated No
Health authority China: National Health and Family Planning Commission
Study type Interventional

Clinical Trial Summary

This study evaluates the incidence of hepatic encephalopathy between covered stent of diameter of 7mm and 8mm in TIPS(transjugular intrahepatic portosystemic stent shunt ).Half of the participants will receive stent of diameter of 7mm ,while the other half will receive stent of diameter of 8mm.


Description:

TIPS is effective in the treatment of hemorrhage of digestive tract and intractable ascites,which are the complications of cirrhosis. At present, the high incidence of hepatic encephalopathy has been a major problem after TIPS. The high incidence rate of hepatic encephalopathy was closly associated with the diameter of the stent. We often use the stent of diameter 8mm in TIPS.In this study, we try to use the stent of smaller diameter of 7mm in TIPS,and compare the incidence of hepatic encephalopathy between the stent of diameter of 7mm and 8mm .


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 216
Est. completion date December 2017
Est. primary completion date December 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. there is a clear TIPS treatment indications of liver cirrhosis portal hypertension patients of gastrointestinal bleeding.

2. undergoing elective TIPS to treat patients.

3. aged 18-70 years old

Exclusion Criteria:

1. preoperative patients with hepatic encephalopathy.

2. with portal vein thrombosis patients.

3. combined liver malignant tumor or other parts of the patients with malignant tumor.

4. In combination of peptic ulcer bleeding.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
the stent of diameter of 7mm
108 patients use the stent of diameter of 7mm in TIPS
the stent of diameter of 8mm
108 patients use the stent of diameter of 8mm in TIPS

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Beijing Shijitan Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence of hepatic encephalopathy after TIPS The incidence of hepatic encephalopathy after TIPS in 7day,1,3,6,12month 1 year No
Secondary the incidence of shunt restenosis after TIPS The incidence of shunt restenosis after TIPS in 7day,1,3,6,12month 1 year No
Secondary the recurrence rate of gastrointestinal bleeding after TIPS The recurrence rate of gastrointestinal bleeding after TIPS in 7day,1,3,6,12month 1 year No
Secondary Portal venous pressure before and afterTIPS Portal venous pressure before and afterTIPS. 1 year No
Secondary liver function in different periods liver function during different periods before and after TIPS in 7day,1,3,6,12month 1 year No
Secondary blood ammonia in different periods blood ammonia before and after TIPS in 7day,1,3,6,12month 1 year No
Secondary jaundice index in different periods jaundice index before and after TIPS in 7day,1,3,6,12month 1 year No
Secondary platelet count in different periods platelet count before and after TIPS in 7day,1,3,6,12month 1 year No
See also
  Status Clinical Trial Phase
Completed NCT02798861 - Controlled Attenuation Parameter (CAP) in Liver Allografts
Completed NCT01968395 - Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Phase 4
Completed NCT01437969 - Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.
Recruiting NCT00155376 - Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Phase 4
Recruiting NCT00172705 - Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique N/A
Completed NCT04185454 - Estimation of Minimum Efficacy Daily Dose of Jarlsberg Cheese N/A
Completed NCT02506335 - Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease Early Phase 1
Completed NCT02520609 - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Completed NCT02306018 - Evaluation of a New Calibrated Pulse Wave Analysis Method(EV1000™/volumeView™) for Cardiac Output Monitoring in Adult Liver Transplantation N/A
Completed NCT01970904 - Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients N/A
Completed NCT01988753 - Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Terminated NCT00741117 - Conjugated Hyperbilirubinemia and Pulse Oximetry N/A
Enrolling by invitation NCT01483248 - Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis Phase 1/Phase 2
Completed NCT00074386 - Kidney and Liver Transplantation in People With HIV N/A
Completed NCT00245830 - Ischemic Preconditioning of Liver in Cadaver Donors N/A
Completed NCT02329821 - Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic Resection N/A
Completed NCT01303549 - Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients Phase 4
Completed NCT01650181 - Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Phase 4
Completed NCT00799851 - A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices Phase 4
Completed NCT00058890 - Gabapentin to Treat Itch in Patients With Liver Disease Phase 3